Mersana Therapeutics Inc (MRSN)

$2.85

-0.36

(-11.21%)▲

Live

Insights on Mersana Therapeutics Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 7.69M → 10.70M (in $), with an average increase of 28.1% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 4 quarters, -57.14M → -19.54M (in $), with an average increase of 49.6% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 50.9% return, outperforming this stock by 73.6%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 247.4% return, outperforming this stock by 327.4%

Performance

  • $2.82
    $3.24
    $2.85
    downward going graph

    1.23%

    Downside

    Day's Volatility :13.12%

    Upside

    12.04%

    downward going graph
  • $0.80
    $9.62
    $2.85
    downward going graph

    71.88%

    Downside

    52 Weeks Volatility :91.67%

    Upside

    70.37%

    downward going graph

Returns

PeriodMersana Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
2.56%
1.9%
0.0%
6 Months
142.26%
10.7%
0.0%
1 Year
-22.65%
4.6%
-1.1%
3 Years
-81.1%
14.2%
-22.1%

Highlights

Market Capitalization
382.1M
Book Value
$0.31
Earnings Per Share (EPS)
-1.48
PEG Ratio
0.0
Wall Street Target Price
6.71
Profit Margin
0.0%
Operating Margin TTM
-195.57%
Return On Assets TTM
-38.13%
Return On Equity TTM
-266.24%
Revenue TTM
36.9M
Revenue Per Share TTM
0.32
Quarterly Revenue Growth YOY
-27.1%
Gross Profit TTM
-146.8M
EBITDA
-169.4M
Diluted Eps TTM
-1.48
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.67
EPS Estimate Next Year
-0.73
EPS Estimate Current Quarter
-0.16
EPS Estimate Next Quarter
-0.2

Analyst Recommendation

Buy
    46%Buy
    46%Hold
    6%Sell
Based on 15 Wall street analysts offering stock ratings for Mersana Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
7
7
7
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 135.44%

Current $2.85
Target $6.71

Company Financials

FY18Y/Y Change
Revenue
10.6M
↓ 39.62%
Net Income
-64.3M
↑ 66.01%
Net Profit Margin
-606.54%
↓ 385.92%
FY19Y/Y Change
Revenue
42.1M
↑ 297.61%
Net Income
-27.2M
↓ 57.67%
Net Profit Margin
-64.57%
↑ 541.97%
FY20Y/Y Change
Revenue
828.0K
↓ 98.03%
Net Income
-88.4M
↑ 225.05%
Net Profit Margin
-10.7K%
↓ 10612.24%
FY21Y/Y Change
Revenue
43.0K
↓ 94.81%
Net Income
-169.2M
↑ 91.4%
Net Profit Margin
-393.5K%
↓ 382823.19%
FY22Y/Y Change
Revenue
26.6M
↑ 61716.28%
Net Income
-207.5M
↑ 22.66%
Net Profit Margin
-780.78%
↑ 392719.22%
FY23Y/Y Change
Revenue
36.9M
↑ 38.65%
Net Income
-171.7M
↓ 17.28%
Net Profit Margin
-465.8%
↑ 314.98%
Q3 FY22Q/Q Change
Revenue
5.6M
↑ 30.09%
Net Income
-60.7M
↑ 14.56%
Net Profit Margin
-1.1K%
↑ 147.65%
Q4 FY22Q/Q Change
Revenue
14.7M
↑ 163.56%
Net Income
-45.9M
↓ 24.39%
Net Profit Margin
-312.42%
↑ 776.6%
Q1 FY23Q/Q Change
Revenue
7.8M
↓ 46.88%
Net Income
-57.1M
↑ 24.53%
Net Profit Margin
-732.45%
↓ 420.03%
Q2 FY23Q/Q Change
Revenue
10.7M
↑ 36.55%
Net Income
-54.3M
↓ 4.97%
Net Profit Margin
-509.73%
↑ 222.72%
Q3 FY23Q/Q Change
Revenue
7.7M
↓ 27.75%
Net Income
-41.7M
↓ 23.3%
Net Profit Margin
-541.13%
↓ 31.4%
Q4 FY23Q/Q Change
Revenue
10.7M
↑ 39.01%
Net Income
-19.5M
↓ 53.08%
Net Profit Margin
-182.64%
↑ 358.49%
FY18Y/Y Change
Total Assets
78.5M
↓ 39.94%
Total Liabilities
69.7M
↑ 14.8%
FY19Y/Y Change
Total Assets
107.5M
↑ 36.99%
Total Liabilities
29.2M
↓ 58.08%
FY20Y/Y Change
Total Assets
273.4M
↑ 154.23%
Total Liabilities
45.3M
↑ 55.06%
FY21Y/Y Change
Total Assets
206.1M
↓ 24.61%
Total Liabilities
84.4M
↑ 86.2%
FY22Y/Y Change
Total Assets
334.3M
↑ 62.21%
Total Liabilities
242.3M
↑ 187.17%
FY23Y/Y Change
Total Assets
226.1M
↓ 32.39%
Total Liabilities
189.2M
↓ 21.93%
Q3 FY22Q/Q Change
Total Assets
314.9M
↑ 24.77%
Total Liabilities
224.6M
↑ 89.85%
Q4 FY22Q/Q Change
Total Assets
334.3M
↑ 6.19%
Total Liabilities
242.3M
↑ 7.86%
Q1 FY23Q/Q Change
Total Assets
296.2M
↓ 11.41%
Total Liabilities
231.9M
↓ 4.29%
Q2 FY23Q/Q Change
Total Assets
311.0M
↑ 5.0%
Total Liabilities
221.2M
↓ 4.61%
Q3 FY23Q/Q Change
Total Assets
262.9M
↓ 15.46%
Total Liabilities
210.7M
↓ 4.74%
Q4 FY23Q/Q Change
Total Assets
226.1M
↓ 14.01%
Total Liabilities
189.2M
↓ 10.23%
FY18Y/Y Change
Operating Cash Flow
-55.2M
↑ 29.38%
Investing Cash Flow
87.2M
↓ 187.52%
Financing Cash Flow
1.1M
↓ 98.45%
FY19Y/Y Change
Operating Cash Flow
-67.7M
↑ 22.69%
Investing Cash Flow
-27.3M
↓ 131.3%
Financing Cash Flow
97.7M
↑ 9082.71%
FY20Y/Y Change
Operating Cash Flow
-74.7M
↑ 10.26%
Investing Cash Flow
37.0M
↓ 235.66%
Financing Cash Flow
230.4M
↑ 135.83%
FY21Y/Y Change
Operating Cash Flow
-140.0M
↑ 87.41%
Investing Cash Flow
-648.0K
↓ 101.75%
Financing Cash Flow
63.6M
↓ 72.38%
FY22Y/Y Change
Operating Cash Flow
-49.4M
↓ 64.74%
Investing Cash Flow
-152.7M
↑ 23467.28%
Financing Cash Flow
153.0M
↑ 140.42%
Q3 FY22Q/Q Change
Operating Cash Flow
54.6M
↓ 221.93%
Investing Cash Flow
-16.5M
↓ 81.77%
Financing Cash Flow
10.6M
↓ 73.75%
Q4 FY22Q/Q Change
Operating Cash Flow
-51.2M
↓ 193.83%
Investing Cash Flow
-45.4M
↑ 175.46%
Financing Cash Flow
41.5M
↑ 289.72%
Q1 FY23Q/Q Change
Operating Cash Flow
-29.0M
↓ 43.38%
Investing Cash Flow
1.4M
↓ 103.07%
Financing Cash Flow
21.5M
↓ 48.02%
Q2 FY23Q/Q Change
Operating Cash Flow
-61.8M
↑ 113.18%
Investing Cash Flow
-5.4M
↓ 489.61%
Financing Cash Flow
73.2M
↑ 239.6%

Technicals Summary

Sell

Neutral

Buy

Mersana Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Mersana Therapeutics Inc
Mersana Therapeutics Inc
-24.82%
142.26%
-22.65%
-81.1%
-28.98%
Moderna, Inc.
Moderna, Inc.
-2.26%
35.27%
-21.9%
-39.25%
318.83%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-5.59%
12.81%
13.84%
81.04%
166.5%
Novo Nordisk A/s
Novo Nordisk A/s
-0.32%
31.91%
50.92%
247.21%
431.9%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-2.67%
9.62%
21.65%
86.62%
134.62%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Mersana Therapeutics Inc
Mersana Therapeutics Inc
NA
NA
0.0
-0.67
-2.66
-0.38
NA
0.31
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.9
25.9
1.46
45.02
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
47.09
47.09
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.81
28.81
0.53
16.76
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Mersana Therapeutics Inc
Mersana Therapeutics Inc
Buy
$382.1M
-28.98%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$40.0B
318.83%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.8B
166.5%
25.9
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$558.9B
431.9%
47.09
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$103.4B
134.62%
28.81
36.68%

Institutional Holdings

  • EcoR1 Capital, LLC

    15.96%

  • VR Adviser, LLC

    9.34%

  • Balyasny Asset Management LLC

    8.00%

  • Bain Capital Life Sciences Investors, LLC

    7.14%

  • BlackRock Inc

    6.47%

  • SILVERARC CAPITAL MANAGEMENT, LLC

    5.29%

Corporate Announcements

  • Mersana Therapeutics Inc Earnings

    Mersana Therapeutics Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

mersana is rewriting the rules for immunoconjugate therapies by leveraging our fleximer platform to create precisely targeted and highly tailored drugs that radically improve patients’ lives. our fleximer platform allows us to custom design an adc with specific properties to overcome limitations of current adc approaches and increase the drug’s chances of effectively attacking a particular cancer. we engineer immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. because we can safely deliver higher quantities of therapeutic payloads directly to a tumor, mersana’s adc therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today’s cancer treatments.

Organization
Mersana Therapeutics Inc
Employees
123
CEO
Dr. Martin H. Huber M.D.
Industry
Health Technology

Discover More

FAQs